‘A chilling effect’: China biotech will slow as it nears R&D frontier, Pfizer’s Baum predicts

Pfizer's Andrew Baum says China's biotech advance will slow as R&D risks mount, predicting tighter IIT trial rules after two gene-therapy patient deaths.

Raccontata daendpoints.news